Doses above recommended levels have not been shown to cause harm
MENLO PARK, Calif., May 7, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, in partnership with Mayo Clinic researchers, presented new findings at Digestive Disease Week (DDW) 2025 showing its proprietary machine-learning algorithms can predict which patients are more likely to experience side effects, specifically nausea, from GLP-1 therapies
We want all these signs to show, Hey, The metabolic dysfunction and the loss of metabolic potency that led you to the point of not being able to influence your weight appropriately, we want proof and data that shows that that's reversed
Prebiotic potential and anti-inflammatory activity of soluble polysaccharides obtained from soybean residue
Vitamins and nutritional supplements are the most popular at 42%, followed by protein/nutrition shakes and powders at 37%